Close



Apr 14, 2022 07:00AM
Jan 11, 2022 04:06PM
Jan 11, 2022 04:05PM
Dec 30, 2021 08:02AM
Dec 30, 2021 08:00AM
Dec 10, 2021 08:00AM
Dec 1, 2021 09:32AM H.C. Wainwright Downgrades BeyondSpring Inc. (BYSI) to Neutral
Dec 1, 2021 08:01AM
Dec 1, 2021 08:00AM
Nov 30, 2021 11:08AM
Nov 29, 2021 11:29AM
Nov 24, 2021 05:09AM
Nov 19, 2021 04:04AM
Nov 18, 2021 04:18AM BeyondSpring (BYSI) call put ratio 1 call to 1.5 puts
Nov 17, 2021 02:05PM
Nov 11, 2021 04:26AM
Nov 10, 2021 04:57AM
Oct 21, 2021 07:00AM
Oct 20, 2021 07:00AM
Oct 18, 2021 05:16AM
Sep 20, 2021 07:32AM BeyondSpring (BYSI) Announces Positive Final Phase 3 DUBLIN-3 Data with Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line NSCLC Patients with EGFR Wild Type at ESMO
Sep 20, 2021 07:30AM
Sep 16, 2021 07:04AM
Sep 16, 2021 07:00AM
Sep 9, 2021 07:00AM
Aug 31, 2021 07:03AM
Aug 31, 2021 07:00AM
Aug 26, 2021 07:11AM BeyondSpring (BYSI) Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
Aug 26, 2021 07:00AM
Aug 10, 2021 08:00AM
Aug 4, 2021 07:02AM
Aug 4, 2021 07:00AM
Jul 14, 2021 07:35AM
Jul 14, 2021 07:30AM
Jun 17, 2021 04:00PM BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
Jun 17, 2021 06:52AM
Jun 16, 2021 08:00AM
Jun 10, 2021 07:11AM
Jun 10, 2021 07:00AM
Jun 8, 2021 07:09AM
Jun 8, 2021 07:00AM
Jun 7, 2021 07:05AM BeyondSpring (BYSI) to Present Three Abstracts from PROTECTIVE-2 Phase 3 Trials of Plinabulin at ASCO
Jun 7, 2021 07:00AM
Jun 4, 2021 07:00AM
Jun 1, 2021 07:03AM
Jun 1, 2021 07:00AM
May 24, 2021 07:34AM
May 24, 2021 07:30AM
Apr 30, 2021 07:00AM BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update
Mar 31, 2021 11:20PM

251,817 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All